⌕
AnaptysBio · ANAB · Nasdaq
Tenet 53 · Mixed
Compare
$45.61−0.26%At closeTenet 53 · Mixed
$45.61−0.12 (−0.26%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

AnaptysBio (ANAB) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ANAB's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 16:32 ET
AnaptysBio, Inc. (ANAB) Presents at UBS Global Biopharma Conference 2026 Transcript

AnaptysBio, Inc. ( ANAB ) UBS Global Biopharma Conference 2026 November 17, 2026 11:40 AM EST Company Participants Daniel Faga - President, CEO & Director Conference Call Participants Madeleine Lee - UBS Investment Bank,…

ANAB −0.3% todayRead at source ↗
● Zacks Investment ResearchNov 12, 2026 · 19:06 ETEARNINGS EXPECTED BY FEB 19
AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.52 per share a year ago.…

ANAB −0.3% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 16:15 ETEARNINGS EXPECTED BY FEB 19
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, tod…

ANAB −0.3% todayRead at source ↗
● GlobeNewsWireNov 10, 2026 · 16:20 ET
Anaptys Announces Participation in Upcoming Investor Conferences

SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, tod…

ANAB −0.3% todayRead at source ↗
● Zacks Investment ResearchOct 27, 2026 · 11:00 ETEARNINGS EXPECTED BY FEB 19
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?

AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

ANAB −0.3% todayRead at source ↗
● GlobeNewsWireOct 19, 2026 · 14:18 ET
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, tod…

ANAB −0.3% todayRead at source ↗
● Zacks Investment ResearchSep 21, 2026 · 18:35 ETEARNINGS EXPECTED BY FEB 19
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.34 per share a year ago.…

ANAB −0.3% todayRead at source ↗
● GlobeNewsWireSep 21, 2026 · 16:15 ETEARNINGS EXPECTED BY FEB 19
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, to…

ANAB −0.3% todayRead at source ↗
● GlobeNewsWireSep 1, 2026 · 16:15 ET
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murph…

ANAB −0.3% todayRead at source ↗
● Defense WorldSep 1, 2026 · 04:03 ETEARNINGS EXPECTED BY FEB 19
16,500 Shares in AnaptysBio, Inc. $ANAB Bought by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board purchased a new stake in AnaptysBio, Inc. (NASDAQ: ANAB) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The…

ANAB −0.3% todayRead at source ↗

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 19. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just ANAB · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.